← Back to Search

Other

Cisplatin for Pancreatic Cancer

Phase 2
Waitlist Available
Research Sponsored by CanBas Co. Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Summary

This trial tests combinations of three drugs to treat advanced pancreatic cancer. It targets patients with advanced cancer and specific blood cell counts. The drugs work by killing cancer cells and helping the immune system fight the cancer. Gemcitabine has been a cornerstone in the treatment of advanced pancreatic cancer, often used in combination with other drugs to improve efficacy.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Three-month progression free survival rate (3M PFSR)
Secondary study objectives
Confirmed and timepoint objective response rates (cORR/ORR)
Duration of responses (DoR)
Overall survival (OS)
+3 more

Side effects data

From 2012 Phase 3 trial • 256 Patients • NCT01005680
51%
Neutropenia
47%
Leukopenia
46%
Nausea
43%
Vomiting
35%
Anaemia
31%
Decreased appetite
26%
Haemoglobin decreased
26%
Fatigue
25%
Constipation
25%
White blood cell count decreased
24%
Neutrophil count decreased
19%
Alanine aminotransferase increased
13%
Platelet count decreased
12%
Rash
10%
Aspartate aminotransferase increased
10%
Thrombocytopenia
9%
Blood sodium decreased
8%
Hypokalaemia
7%
Insomnia
7%
Pyrexia
6%
Hyponatraemia
6%
Blood creatinine increased
6%
Lymphopenia
6%
Diarrhoea
6%
Dyspepsia
6%
Red blood cell count decreased
6%
Cough
4%
Dizziness
2%
Bone marrow failure
1%
Cerebral infarction
1%
Dyspnoea
1%
Ischaemic stroke
1%
Pulmonary embolism
1%
Embolism venous
1%
Superior vena cava syndrome
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gemcitabine Plus Cisplatin (GC)
Pemetrexed Plus Cisplatin (PC)

Trial Design

4Treatment groups
Experimental Treatment
Group I: Arm 4: Cisplatin + NivolumabExperimental Treatment2 Interventions
Cisplatin 60mg/m2 will be administered as infusion and then Nivolumab 240mg will be administered.
Group II: Arm 3: CBP501 (25) + CisplatinExperimental Treatment2 Interventions
CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously.
Group III: Arm 2: CBP501 (16) + Cisplatin + NivolumabExperimental Treatment3 Interventions
CBP501 16mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
Group IV: Arm 1: CBP501 (25) + Cisplatin + NivolumabExperimental Treatment3 Interventions
CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~5220
CBP501 (25)
2021
Completed Phase 2
~40
CBP501 (16)
2021
Completed Phase 2
~40
Cisplatin
2013
Completed Phase 3
~3120

Find a Location

Who is running the clinical trial?

CanBas Co. Ltd.Lead Sponsor
4 Previous Clinical Trials
359 Total Patients Enrolled
~10 spots leftby Oct 2025